FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952017838> ?p ?o ?g. }

• W2952017838 endingPage "335" @default.
• W2952017838 startingPage "334" @default.
• W2952017838 abstract "Background: T cell depletion (TCD) decreases Graft Versus Host Disease (GvHD) risk after allogeneic stem cell transplantation (alloSCT). In order to induce a Graft Versus Leukemia (GvL) effect, post-transplantation cellular interventions are applied. Combination of ex vivo and in vivo Alemtuzumab, with Thymoglobulin only for unrelated donors (UD), can obviate the need for post-transplantation prophylactic immunosuppression, enabling early cellular interventions starting at 2 months after alloSCT after clearance of circulating therapeutic antibodies. Aims: To evaluate whether early prophylactic cellular interventions after Alemtuzumab based TCD alloSCT can restore GvL effect leading to enduring relapse-free survival without chronic GvHD. Methods: AML patients who received TCD alloSCT between April 2010 and August 2016 from a 10/10 HLA matched donor after reduced intensity conditioning (6 days 50 mg/m2 Fludarabin a day orally and 2 days Busulphan 3.2 mg/kg intravenously) were included in this analysis. TCD was performed by Alemtuzumab (20 mg ex vivo and 30 mg in vivo) with addition of 1 mg/kg Thymoglobulin in vivo for patients with UD. No standard GvHD prophylaxis nor anti leukemia chemotherapy was given after alloSCT. Goal of this strategy was to give donor derived T cell products as part of clinical trials as early as 8 weeks after alloSCT or standard unmodified donor lymphocytes (DLI) starting at 12 weeks after alloSCT in the absence of GvHD. A competing risks model was built with study T cell products, unmodified DLI, therapeutic immunosuppression (tIS) for GvHD, relapse and death as competing events. tIS was not considered a failure, since GvHD after alloSCT in this setting could be associated with GvL effect, but was not the goal of this strategy. Chronic GvHD was evaluated by measuring use of tIS in surviving relapse-free patients at 2 years after alloSCT. Long term outcomes were evaluated at 4 years, with a minimal follow-up time of 2 years after alloSCT. Results: 80 AML patients (29 with related donor (RD), 51 UD) were included with median age of 63 (range 44–76) and median Gratwohl score of 3 (range 2–6). All patients engrafted. Cumulative incidences of reaching the predefined endpoints are shown in figures 1A-B. At 7.5 months after alloSCT, all patients with a RD had reached a relevant endpoint: received a cellular intervention (79%, 95% CI 65–94), started tIS after alloSCT (7%, 95% CI 0–16), or relapsed (14%, 95% CI 1–26) before cellular intervention could be given. For patients with UD, 1-year probabilities were 78% (95% CI 67–90) for reaching planned cellular intervention and 8% (95% CI 0–15) for both relapse and death without event. No patient with UD needed tIS after alloSCT. As shown in figures 1C-D, overall survival at 4 years after alloSCT was 60% (95% CI 39–81) and 50% (95% CI 35–64) for patients with RD and UD, respectively, with relapse-free survival of 60% (95% CI 40–81) and 43% (95% CI 29–58). Of the 47 patients still alive without relapse at 2 years after alloSCT, 83% (95% CI 69–92) did not need tIS at that time.Summary/Conclusion: A strategy of Alemtuzumab based TCD alloSCT without post-transplantation prophylactic immunosuppression followed by prophylactic cellular interventions starting at 2 months is feasible in older and frail AML patients. This strategy led to a low relapse risk with 4-year relapse-free survival of 60% and 43% for patients with related and unrelated donor, respectively. At 2 years, only 17% of surviving relapse-free patients needed long term immunosuppression for chronic GvHD." @default.
• W2952017838 created "2019-06-27" @default.
• W2952017838 creator A5001027484 @default.
• W2952017838 creator A5003531307 @default.
• W2952017838 creator A5008348771 @default.
• W2952017838 creator A5012790914 @default.
• W2952017838 creator A5019210345 @default.
• W2952017838 creator A5031179518 @default.
• W2952017838 creator A5044734549 @default.
• W2952017838 creator A5046125646 @default.
• W2952017838 creator A5048105812 @default.
• W2952017838 creator A5061886939 @default.
• W2952017838 date "2019-06-01" @default.
• W2952017838 modified "2023-09-27" @default.
• W2952017838 title "PF761 REDUCED INTENSITY CONDITIONING REGIMEN WITH ALEMTUZUMAB BASED T CELL DEPLETION ENABLES EARLY POST-TRANSPLANTATION CELLULAR INTERVENTION RESTORING GRAFT VERSUS LEUKEMIA EFFECTS IN OLDER AML PATIENTS" @default.
• W2952017838 doi "https://doi.org/10.1097/01.hs9.0000561328.67597.79" @default.
• W2952017838 hasPublicationYear "2019" @default.
• W2952017838 type Work @default.
• W2952017838 sameAs 2952017838 @default.
• W2952017838 citedByCount "0" @default.
• W2952017838 crossrefType "journal-article" @default.
• W2952017838 hasAuthorship W2952017838A5001027484 @default.
• W2952017838 hasAuthorship W2952017838A5003531307 @default.
• W2952017838 hasAuthorship W2952017838A5008348771 @default.
• W2952017838 hasAuthorship W2952017838A5012790914 @default.
• W2952017838 hasAuthorship W2952017838A5019210345 @default.
• W2952017838 hasAuthorship W2952017838A5031179518 @default.
• W2952017838 hasAuthorship W2952017838A5044734549 @default.
• W2952017838 hasAuthorship W2952017838A5046125646 @default.
• W2952017838 hasAuthorship W2952017838A5048105812 @default.
• W2952017838 hasAuthorship W2952017838A5061886939 @default.
• W2952017838 hasBestOaLocation W29520178381 @default.
• W2952017838 hasConcept C126322002 @default.
• W2952017838 hasConcept C141071460 @default.
• W2952017838 hasConcept C143998085 @default.
• W2952017838 hasConcept C203014093 @default.
• W2952017838 hasConcept C2777630719 @default.
• W2952017838 hasConcept C2777938653 @default.
• W2952017838 hasConcept C2778461978 @default.
• W2952017838 hasConcept C2779015954 @default.
• W2952017838 hasConcept C2779972918 @default.
• W2952017838 hasConcept C2780252810 @default.
• W2952017838 hasConcept C2909675724 @default.
• W2952017838 hasConcept C2911091166 @default.
• W2952017838 hasConcept C71924100 @default.
• W2952017838 hasConceptScore W2952017838C126322002 @default.
• W2952017838 hasConceptScore W2952017838C141071460 @default.
• W2952017838 hasConceptScore W2952017838C143998085 @default.
• W2952017838 hasConceptScore W2952017838C203014093 @default.
• W2952017838 hasConceptScore W2952017838C2777630719 @default.
• W2952017838 hasConceptScore W2952017838C2777938653 @default.
• W2952017838 hasConceptScore W2952017838C2778461978 @default.
• W2952017838 hasConceptScore W2952017838C2779015954 @default.
• W2952017838 hasConceptScore W2952017838C2779972918 @default.
• W2952017838 hasConceptScore W2952017838C2780252810 @default.
• W2952017838 hasConceptScore W2952017838C2909675724 @default.
• W2952017838 hasConceptScore W2952017838C2911091166 @default.
• W2952017838 hasConceptScore W2952017838C71924100 @default.
• W2952017838 hasIssue "S1" @default.
• W2952017838 hasLocation W29520178381 @default.
• W2952017838 hasLocation W29520178382 @default.
• W2952017838 hasOpenAccess W2952017838 @default.
• W2952017838 hasPrimaryLocation W29520178381 @default.
• W2952017838 hasRelatedWork W1600771015 @default.
• W2952017838 hasRelatedWork W1964681599 @default.
• W2952017838 hasRelatedWork W1966299088 @default.
• W2952017838 hasRelatedWork W1968059227 @default.
• W2952017838 hasRelatedWork W1970639014 @default.
• W2952017838 hasRelatedWork W2032596326 @default.
• W2952017838 hasRelatedWork W2065448696 @default.
• W2952017838 hasRelatedWork W2065729608 @default.
• W2952017838 hasRelatedWork W2160634976 @default.
• W2952017838 hasRelatedWork W4366607347 @default.
• W2952017838 hasVolume "3" @default.
• W2952017838 isParatext "false" @default.
• W2952017838 isRetracted "false" @default.
• W2952017838 magId "2952017838" @default.
• W2952017838 workType "article" @default.